						C			
Sheet 1 of 1	4)	. #	INFORMA	TION DISCLOSURE STATEMENT			9 0	u	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE B 1 7 1005 U.S. OEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE U.S. OEPARTMENT OF COMMERCE U.S. OEPARTMENT OF COMERCE U.S. OEPARTMENT OF COMMERCE U.S. OEPARTMENT OF C				ATTY DOCKET NO. 2005_1807A	SERIAL (OIPE	(ADE	
				APPLICANT Toshikazu NAKAMURA et al. SEP 1 5 2008			18 (8)		
				FILING DATE December 6, 2005			\$		
حب			U	S. PATENT DOCUMENTS	_				
*EXAMINER INITIAL	<u> </u>	DOCUMENT NUMBER	OATE	NAME	CLASS	SUBCLASS	FILING D APPROF		
	AA								
	A8				THE CO	MMISSIONER	IIS ATTHOU	ızen —	
	AC				FEES FOR THIS PAPER TO		ICIENCY IN		
	AD				ACCOU	NT NO. 23-09	75		
	AE			<u> </u>	<u> </u>				
	_	1	. FOR	EIGN PATENT DOCUMENTS					
	_	DOCUMENT NUMBER	OATE	COUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO	
/ML/	AF	92/06702	4/1992	wo					
/ML/	AG	00/61156	10/2000	wo				<u> </u>	
	AH							ļ	
<u> </u>	Al				<u> </u>				
		OTHER O	OCUMENT(S) (In	cluding Author, Title, Date, Pertin	ent Pages, Etc.)				
/ML/	AJ	Kuba et al., "Organ 2450, 2002. (with	Regeneration English trans	by HGF and Cancer Therelation of the Abstract and	rapy by NK4", <u>J</u> d Column 5 on p	ikken Igaku, \ bages 2147-2	Vol. 20, pp. 149)	2143-	
	AK	Mayumi, "Overview of Regeneration and DDS - from pharmacological viewpoint", <u>Drug Delivery System</u> , Vol. 16, pp. 10-16, 2001.							
	AL	Mayumi, "The Paradigm Shift of the Drug Concept - for disease treatment by large molecular medicines", <u>Journal of Japanese Cosmetic Science Society Gakkai-Shi</u> , Vol. 26, pp. 234-238, 2002. (with English translation of the 3", 9" and 10" paragraphs of the article)							
	АМ	Ikada, "Overview", <u>Protein, Nucleic Acid and Enzyme</u> , Vol. 45, pp. 2139-2141, 2000. (with its English Translation)							
	AO	2142-2149, 2000.	(with English	of Biodegradable Polymer' n translation of the Abstra 2144-2145, and Conclusi	ct and Introduc	tion on page 2	nzyme, Vol. 2142, Colun	45, pp. nn 1 on	
V	AP	Manabe et al., "Cel transduced Oral Mu	I-based Protei	n Delivery System for the al Cell Sheet", Clinical Ca	Growth of Pani	creatic Cancer	r: NK4 Gene	-	

*EXAMINER: Initial if reference considered, whether or not clistion is in conformance with MPEP 603; Draw line through clistion if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

/Maria Leavitt/

EXAMINER

12/23/2008